Nanox Imaging Ltd. (NASDAQ: NNOX) has taken a significant step toward expanding its presence in the United Kingdom’s healthcare market by signing an exclusive reseller agreement with Vertec Scientific Ltd. The partnership, announced through a press release, grants Vertec the exclusive rights to market and resell Nanox’s AI-powered bone health solution, HealthOST, across the UK. The agreement includes minimum annual license commitments and spans an initial three-year term, underscoring the strategic importance of the UK market for Nanox’s growth plans.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to help clinicians evaluate musculoskeletal diseases of the spine, including osteoporosis. This technology is designed to support opportunistic detection of vertebral fragility fractures, a condition often underdiagnosed. The solution’s clinical value was reinforced in November 2025 when the National Institute for Health and Care Excellence (NICE) recommended HealthOST and its predecessor, HealthVCF, among five AI technologies for use in the National Health Service (NHS). This recommendation positions HealthOST as a viable option for NHS trusts looking to integrate AI-driven diagnostics into standard care pathways.
The exclusive agreement with Vertec Scientific, a well-established supplier of medical equipment in the UK, is expected to accelerate the adoption of HealthOST within the NHS. By leveraging Vertec’s distribution network and customer relationships, Nanox aims to make its AI solution more accessible to healthcare providers, potentially improving early detection of osteoporosis and reducing the burden of fractures on the healthcare system. Osteoporosis-related fractures are a major public health concern, particularly among the elderly, and early identification through routine CT scans could lead to timely interventions and better patient outcomes.
For Nanox, this partnership aligns with its broader mission of transitioning healthcare toward preventive models. The company, which describes itself as a leader in innovative medical imaging, is building an integrated ecosystem that includes affordable imaging hardware like the Nanox.ARC, AI-based solutions, cloud-based software, and teleradiology services. The UK reseller agreement is a key component of Nanox’s strategy to expand its AI offerings globally, following regulatory clearances and positive health technology assessments.
The move also reflects a growing trend in healthcare where AI-powered tools are being integrated into routine imaging workflows. NICE’s endorsement of AI technologies for opportunistic fracture detection signals a shift toward more proactive and efficient use of existing medical data. For healthcare leaders, this development highlights the potential of AI to enhance diagnostic accuracy without requiring additional imaging procedures, thereby optimizing resource utilization and improving patient care.
Industry observers note that the UK market presents a significant opportunity for AI diagnostic companies, given the NHS’s emphasis on innovation and value-based care. The exclusive agreement with Vertec could set a precedent for other AI vendors seeking to enter the NHS market. Moreover, the three-year commitment and minimum license requirements indicate a high level of confidence in HealthOST’s clinical and commercial viability.
Nanox’s expansion into the UK comes at a time when the global medical AI market is poised for substantial growth. With regulatory approvals and clinical endorsements in place, the company is well-positioned to capture market share in the UK and potentially other regions. The partnership with Vertec is expected to drive revenue growth for Nanox while contributing to the broader goal of improving musculoskeletal health outcomes.
As healthcare systems worldwide grapple with aging populations and rising chronic disease burdens, AI solutions like HealthOST offer a practical, scalable approach to early detection and intervention. The UK reseller agreement marks a milestone in Nanox’s journey to make advanced diagnostic tools more accessible, potentially influencing how similar technologies are adopted in other national health systems.
